Top

Current Neurology and Neuroscience Reports

Published in:

01-12-2015 | Behavior (HS Kirshner, Section Editor)

Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease

Authors: Katherine E. McDonell, Cyndya A. Shibao, Daniel O. Claassen

Published in: Current Neurology and Neuroscience Reports | Issue 12/2015

Abstract

The autonomic nervous system appears to be uniquely susceptible to degeneration in disorders of α-synuclein pathology. Clinically, autonomic dysfunction in these disorders manifests as neurogenic orthostatic hypotension (nOH), a condition that results in substantial morbidity and mortality. nOH results from pathology affecting either the central autonomic pathways or peripheral autonomic nerve fibers. Determining the localization and pathophysiology of nOH is critical in effectively managing this disorder and selecting appropriate treatment options. In this review, we discuss the pathophysiology of nOH with respect to the various α-synuclein-related neurodegenerative conditions. We highlight the associated clinical features, including gait instability, rapid eye movement behavior disorder, and hyposmia. We also review the current pharmacologic treatment options for nOH. Overall, the goals of therapy are to improve symptoms and prevent syncope and falls. Non-pharmacologic interventions should be introduced first, followed by carefully selected pharmacologic therapies. Treatment decisions should be directed by an understanding of the underlying pathophysiology, as well as the comorbidities and potential contributing factors present in each individual patient.

Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72. doi:10.1007/s10286-011-0119-5.CrossRefPubMed

Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139–46. doi:10.1161/CIRCULATIONAHA.108.805887.PubMedCentralCrossRefPubMed

Cersosimo MG, Benarroch EE. Central control of autonomic function and involvement in neurodegenerative disorders. Handb Clin Neurol. 2013;117:45–57. doi:10.1016/B978-0-444-53491-0.00005-5.CrossRefPubMed

Benarroch EE. The arterial baroreflex: functional organization and involvement in neurologic disease. Neurology. 2008;71(21):1733–8. doi:10.1212/01.wnl.0000335246.93495.92.CrossRefPubMed

Hague K, Lento P, Morgello S, Caro S, Kaufmann H. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol. 1997;94(2):192–6.CrossRefPubMed

Winston N, Vernino S. Autoimmune autonomic ganglionopathy. Front Neurol Neurosci. 2009;26:85–93. doi:10.1159/000212370.CrossRefPubMed

Biaggioni I, Hollister AS, Robertson D. Dopamine in dopamine-beta-hydroxylase deficiency. N Engl J Med. 1987;317(22):1415–6. doi:10.1056/NEJM198711263172212.CrossRefPubMed

Senard JM, Rouet P. Dopamine beta-hydroxylase deficiency. Orphanet J Rare Dis. 2006;1:7. doi:10.1186/1750-1172-1-7.PubMedCentralCrossRefPubMed

Okada Y, Ito Y, Aida J, Yasuhara M, Ohkawa S, Hirokawa K. Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int. 2004;54(9):682–7. doi:10.1111/j.1440-1827.2004.01680.x.CrossRefPubMed

10.

Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol. 1997;38 Suppl 2:2–7.CrossRefPubMed

11.

Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006;396(1):67–72. doi:10.1016/j.neulet.2005.11.012.CrossRefPubMed

12.

Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014;10:169–76. doi:10.2147/VHRM.S53983.PubMedCentralCrossRefPubMed

13.

Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci. 2011;310(1–2):123–8. doi:10.1016/j.jns.2011.06.047.CrossRefPubMed

14.

Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011;17(8):625–8. doi:10.1016/j.parkreldis.2011.05.020.CrossRefPubMed

15.

Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584–9.PubMedCentralCrossRefPubMed

16.

Horimoto Y, Matsumoto M, Akatsu H, Ikari H, Kojima K, Yamamoto T, et al. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol. 2003;250(5):530–3. doi:10.1007/s00415-003-1029-9.CrossRefPubMed

17.

Kaufmann H, Biaggioni I. Autonomic failure in neurodegenerative disorders. Semin Neurol. 2003;23(4):351–63. doi:10.1055/s-2004-817719.CrossRefPubMed

18.

Oppenheimer DR. Lateral horn cells in progressive autonomic failure. J Neurol Sci. 1980;46(3):393–404.CrossRefPubMed

19.

Benarroch EE. New findings on the neuropathology of multiple system atrophy. Auton Neurosci. 2002;96(1):59–62.CrossRefPubMed

20.•

Arnold AC, Shibao C. Current concepts in orthostatic hypotension management. Curr Hypertens Rep. 2013;15(4):304–12. doi:10.1007/s11906-013-0362-3. Arnold and Shibao provide a comprehensive overview of the causes of orthostatic hypotension and discuss current treatment options. They provide a structured approach to management, including in challenging circumstances such as elderly hypertensive patients and primary autonomic failure with supine hypertension.PubMedCentralCrossRefPubMed

21.

Weiss A, Grossman E, Beloosesky Y, Grinblat J. Orthostatic hypotension in acute geriatric ward: is it a consistent finding? Arch Intern Med. 2002;162(20):2369–74.CrossRefPubMed

22.

Goldstein DS, Holmes C, Sharabi Y, Brentzel S, Eisenhofer G. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology. 2003;60(8):1327–32.CrossRefPubMed

23.

Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T. MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review. Parkinsonism Relat Disord. 2014;20(3):267–73. doi:10.1016/j.parkreldis.2013.11.001.CrossRefPubMed

24.

Goldstein DS, Sewell L. Olfactory dysfunction in pure autonomic failure: implications for the pathogenesis of Lewy body diseases. Parkinsonism Relat Disord. 2009;15(7):516–20. doi:10.1016/j.parkreldis.2008.12.009.PubMedCentralCrossRefPubMed

25.

Garland EM, Raj SR, Peltier AC, Robertson D, Biaggioni I. A cross-sectional study contrasting olfactory function in autonomic disorders. Neurology. 2011;76(5):456–60. doi:10.1212/WNL.0b013e31820a0caf.PubMedCentralCrossRefPubMed

26.

Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014;64(6):1235–40. doi:10.1161/HYPERTENSIONAHA.114.04225.CrossRefPubMed

27.

Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130(Pt 11):2770–88.CrossRefPubMed

28.

Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75(6):494–9. doi:10.1212/WNL.0b013e3181ec7fac.PubMedCentralCrossRefPubMed

29.•

Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013;14(8):744–8. doi:10.1016/j.sleep.2012.10.009. Schenck and Boeve report findings from a 16-year follow up study of 26 men over age 50 with REM behavior disorder. The vast majority of these went on to develop a parkinsonian disorder after an interval of 14–29 years. This study helped to confirm the strong relationship between RBD and synucleinopathies.CrossRefPubMed

30.

Postuma RB, Lanfranchi PA, Blais H, Gagnon JF, Montplaisir JY. Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov Disord. 2010;25(14):2304–10. doi:10.1002/mds.23347.CrossRefPubMed

31.

Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. Brain. 2009;132(Pt 12):3298–307. doi:10.1093/brain/awp244.CrossRefPubMed

32.

Miyamoto T, Miyamoto M, Suzuki K, Nishibayashi M, Iwanami M, Hirata K. 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep. 2008;31(5):717–23.PubMedCentralPubMed

33.••

Postuma RB, Gagnon JF, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. Mov Disord. 2013;28(5):597–604. doi:10.1002/mds.25445. Postuma et al. report the results of a 9-year cohort study following 91 patients with idiopathic RBD who were assessed at yearly intervals for symptoms of autonomic dysfunction, dementia, and parkinsonism. This study demonstrated clear abnormalities in autonomic function 10–20 years prior to the diagnosis of PD or DLB.CrossRefPubMed

34.

Ramaligam V, Chen MC, Saper CB, Lu J. Perspectives on the rapid eye movement sleep switch in rapid eye movement sleep behavior disorder. Sleep Med. 2013;14(8):707–13. doi:10.1016/j.sleep.2013.03.017.PubMedCentralCrossRefPubMed

35.

Kimura K, Tachibana N, Kohyama J, Otsuka Y, Fukazawa S, Waki R. A discrete pontine ischemic lesion could cause REM sleep behavior disorder. Neurology. 2000;55(6):894–5.CrossRefPubMed

36.

Tippmann-Peikert M, Boeve BF, Keegan BM. REM sleep behavior disorder initiated by acute brainstem multiple sclerosis. Neurology. 2006;66(8):1277–9. doi:10.1212/01.wnl.0000208518.72660.ff.CrossRefPubMed

37.

St Louis EK, McCarter SJ, Boeve BF, Silber MH, Kantarci K, Benarroch EE, et al. Lesional REM sleep behavior disorder localizes to the dorsomedial pons. Neurology. 2014;83(20):1871–3. doi:10.1212/WNL.0000000000000978.CrossRefPubMed

38.

Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318(1):121–34. doi:10.1007/s00441-004-0956-9.CrossRefPubMed

39.

Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61(5):413–26.PubMed

40.

Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119(6):689–702. doi:10.1007/s00401-010-0664-3.PubMedCentralCrossRefPubMed

41.

Tamura T, Yoshida M, Hashizume Y, Sobue G. Lewy body-related alpha-synucleinopathy in the spinal cord of cases with incidental Lewy body disease. Neuropathology. 2012;32(1):13–22. doi:10.1111/j.1440-1789.2011.01211.x.CrossRefPubMed

42.

Garcia-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, Leu-Semenescu S, Gallea C, Quattrocchi G, et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain. 2013;136(Pt 7):2120–9. doi:10.1093/brain/awt152.PubMedCentralCrossRefPubMed

43.

Craig GM. Clinical presentation of orthostatic hypotension in the elderly. Postgrad Med J. 1994;70(827):638–42.PubMedCentralCrossRefPubMed

44.

Shaw BH, Robinovitch SN, Claydon VE. Mechanisms underlying the relationships between cardiovascular dysfunction and fall susceptibility in older adults. Clin Auton Res. 2012;22(5):256.

45.

Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson's disease: a systematic review. Parkinsons Dis. 2013;2013:906274.PubMedCentralPubMed

46.

Gray P, Hildebrand K. Fall risk factors in Parkinson's disease. J Neurosci Nurs. 2000;32(4):222–8.CrossRefPubMed

47.

Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry. 2006;77(4):468–73. doi:10.1136/jnnp.2005.074070.PubMedCentralCrossRefPubMed

48.

Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12(2):133–47. doi:10.1002/mds.870120203.CrossRefPubMed

49.

Weryha G, Angelousi A, Diehdiou D, Cuny T. Bone and androgens. Presse Med. 2014;43(2):180–5. doi:10.1016/j.lpm.2012.12.011.CrossRefPubMed

50.

Matinolli M, Korpelainen JT, Korpelainen R, Sotaniemi KA, Myllyla VV. Orthostatic hypotension, balance and falls in Parkinson's disease. Mov Disord. 2009;24(5):745–51. doi:10.1002/mds.22457.CrossRefPubMed

51.

Kerr GK, Worringham CJ, Cole MH, Lacherez PF, Wood JM, Silburn PA. Predictors of future falls in Parkinson disease. Neurology. 2010;75(2):116–24. doi:10.1212/WNL.0b013e3181e7b688.CrossRefPubMed

52.

Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin Auton Res. 2005;15(2):76–82. doi:10.1007/s10286-005-0253-z.CrossRefPubMed

53.

Kim JS, Oh YS, Lee KS. Autonomic nervous system dysfunctions in Parkinson disease patients with depression. Clin Auton Res. 2013;23(5):274.

54.

Heims HC, Critchley HD, Martin NH, Jager HR, Mathias CJ, Cipolotti L. Cognitive functioning in orthostatic hypotension due to pure autonomic failure. Clin Auton Res. 2006;16(2):113–20. doi:10.1007/s10286-006-0318-7.CrossRefPubMed

55.

Frewen J, Savva GM, Boyle G, Finucane C, Kenny RA. Cognitive performance in orthostatic hypotension: findings from a nationally representative sample. J Am Geriatr Soc. 2014;62(1):117–22.CrossRefPubMed

56.

Sambati L, Calandra-Buonaura G, Poda R, Guaraldi P, Cortelli P. Orthostatic hypotension and cognitive impairment: a dangerous association? Neurol Sci. 2014;35(6):951–7. doi:10.1007/s10072-014-1686-8.CrossRefPubMed

57.

Allcock LM, Kenny RA, Mosimann UP, Tordoff S, Wesnes KA, Hildreth AJ, et al. Orthostatic hypotension in Parkinson's disease: association with cognitive decline? Int J Geriatr Psychiatry. 2006;21(8):778–83. doi:10.1002/gps.1562.CrossRefPubMed

58.

Pilleri M, Facchini S, Gasparoli E, Biundo R, Bernardi L, Marchetti M, et al. Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease. J Neurol. 2013;260(1):253–9. doi:10.1007/s00415-012-6627-y.CrossRefPubMed

59.

Peralta C, Stampfer-Kountchev M, Karner E, Kollensperger M, Geser F, Wolf E, et al. Orthostatic hypotension and attention in Parkinson's disease with and without dementia. J Neural Transm. 2007;114(5):585–8. doi:10.1007/s00702-006-0615-2.CrossRefPubMed

60.

Kim JS, Oh YS, Lee KS, Kim YI, Yang DW, Goldstein DS. Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology. 2012;79(13):1323–31. doi:10.1212/WNL.0b013e31826c1acd.PubMedCentralCrossRefPubMed

61.

McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113–24.CrossRefPubMed

62.

Fukuoka S, Hayashida K, Nishiooeda Y, Hirose Y, Miyashita K, Kawano S, et al. Cerebral hypoperfusion in orthostatic hypotension with globally denervated myocardium. J Nucl Med. 1996;37(11):1824–6.PubMed

63.

Siennicki-Lantz A, Lilja B, Elmstahl S. Orthostatic hypotension in Alzheimer's disease: result or cause of brain dysfunction? Aging. 1999;11(3):155–60.PubMed

64.

Rose JC, Mayer SA. Optimizing blood pressure in neurological emergencies. Neurocrit Care. 2004;1(3):287–99. doi:10.1385/NCC:1:3:287.CrossRefPubMed

65.

Poda R, Guaraldi P, Solieri L, Calandra-Buonaura G, Marano G, Gallassi R, et al. Standing worsens cognitive functions in patients with neurogenic orthostatic hypotension. Neurol Sci. 2012;33(2):469–73. doi:10.1007/s10072-011-0746-6.CrossRefPubMed

66.

Xin W, Lin Z, Mi S. Orthostatic hypotension and mortality risk: a meta-analysis of cohort studies. Heart. 2014;100(5):406–13. doi:10.1136/heartjnl-2013-304121.CrossRefPubMed

67.

Stubendorff K, Aarsland D, Minthon L, Londos E. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia. PLoS One. 2012;7(10), e45451. doi:10.1371/journal.pone.0045451.PubMedCentralCrossRefPubMed

68.

Pathak A, Lapeyre-Mestre M, Montastruc JL, Senard JM. Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure. Mov Disord. 2005;20(9):1213–9. doi:10.1002/mds.20571.CrossRefPubMed

69.

Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon D. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med. 1979;301(2):68–73. doi:10.1056/NEJM197907123010202.CrossRefPubMed

70.

Campbell IW, Ewing DJ, Clarke BF. Therapeutic experience with fludrocortisone in diabetic postural hypotension. Br Med J. 1976;1(6014):872–4.PubMedCentralCrossRefPubMed

71.

Hoehn MM. Levodopa-induced postural hypotension. Treatment with fludrocortisone. Arch Neurol. 1975;32(1):50–1.CrossRefPubMed

72.

Shibao C, Grijalva CG, Lipsitz LA, Biaggioni I, Griffin MR. Abstract 366: midodrine is associated with a lower risk of all-cause hospitalizations compared with fludrocortisone in patients with orthostatic hypotension and heart failure. Hypertension. 2013;62(3):A366.

73.

Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. Jama. 1997;277(13):1046–51.CrossRefPubMed

74.

Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology. 1988;38(6):951–6.CrossRefPubMed

75.

Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38–48.CrossRefPubMed

76.

Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. Jama. 2010;304(19):2172–3. doi:10.1001/jama.2010.1695.CrossRefPubMed

77.

Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99(6):604–10.CrossRefPubMed

78.

Pathak A, Raoul V, Montastruc JL, Senard JM. Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. Eur J Clin Pharmacol. 2005;61(5–6):471–4. doi:10.1007/s00228-005-0941-6.CrossRefPubMed

79.

McClellan KJ, Wiseman LR, Wilde MI. Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging. 1998;12(1):76–86.CrossRefPubMed

80.

Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328–35. doi:10.1212/WNL.0000000000000615.PubMedCentralCrossRefPubMed

81.

Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65(1):101–7. doi:10.1161/HYPERTENSIONAHA.114.04035.PubMedCentralCrossRefPubMed

82.

Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinson's Dis. 2014;4(1):57–65. doi:10.3233/JPD-130259.

83.

Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord. 2015;30(5):646–54. doi:10.1002/mds.26086.CrossRefPubMed

84.•

Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther. 2015:1–17. doi:10.1586/14779072.2015.1057504. Kaufmann et al. provide an overview of the current treatment options for nOH and discuss the recent introduction of droxidopa. They review the clinical trials that led to the approval of droxidopa and discuss its potential benefits and limitations .

85.

Okamoto LE, Shibao C, Gamboa A, Choi L, Diedrich A, Raj SR, et al. Synergistic effect of norepinephrine transporter blockade and alpha-2 antagonism on blood pressure in autonomic failure. Hypertension. 2012;59(3):650–6. doi:10.1161/HYPERTENSIONAHA.111.184812.PubMedCentralCrossRefPubMed

86.

Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74(9):1294–8.PubMedCentralCrossRefPubMed

87.

Shibao C, Okamoto LE, Gamboa A, Yu C, Diedrich A, Raj SR, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56(5):847–51. doi:10.1161/HYPERTENSIONAHA.110.154898.PubMedCentralCrossRefPubMed

88.

Onrot J, Goldberg MR, Biaggioni I, Wiley RG, Hollister AS, Robertson D. Oral yohimbine in human autonomic failure. Neurology. 1987;37(2):215–20.CrossRefPubMed

89.

Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007;50(1):47–53. doi:10.1161/HYPERTENSIONAHA.107.089961.CrossRefPubMed

90.

Arnold AC, Ramirez CE, Choi L, Okamoto LE, Gamboa A, Diedrich A, et al. Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure. Front Physiol. 2014;5:270. doi:10.3389/fphys.2014.00270.PubMedCentralCrossRefPubMed

91.

Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13(9):930–6. doi:10.1111/j.1468-1331.2006.01512.x.CrossRefPubMed

92.

Shannon JR, Jordan J, Diedrich A, Pohar B, Black BK, Robertson D, et al. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000;101(23):2710–5.CrossRefPubMed

93.

Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic failure and its treatment. Hypertension. 1997;30(5):1062–7.CrossRefPubMed

94.

Garland EM, Gamboa A, Okamoto L, Raj SR, Black BK, Davis TL, et al. Renal impairment of pure autonomic failure. Hypertension. 2009;54(5):1057–61. doi:10.1161/HYPERTENSIONAHA.109.136853.PubMedCentralCrossRefPubMed

95.

Vagaonescu TD, Saadia D, Tuhrim S, Phillips RA, Kaufmann H. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet. 2000;355(9205):725–6. doi:10.1016/S0140-6736(99)05320-9.CrossRefPubMed

96.

Jordan J, Shannon JR, Pohar B, Paranjape SY, Robertson D, Robertson RM, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol. 1999;10(1):35–42.PubMed

97.

Shibao C, Gamboa A, Abraham R, Raj SR, Diedrich A, Black B, et al. Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension. 2006;47(3):522–6. doi:10.1161/01.HYP.0000199982.71858.11.CrossRefPubMed

98.

Arnold AC, Okamoto LE, Gamboa A, Shibao C, Raj SR, Robertson D, et al. Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure. Hypertension. 2013;61(3):701–6. doi:10.1161/HYPERTENSIONAHA.111.00377.PubMedCentralCrossRefPubMed

Title: Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease
Authors: Katherine E. McDonell
Cyndya A. Shibao
Daniel O. Claassen
Publication date: 01-12-2015
Publisher: Springer US
Published in: Current Neurology and Neuroscience Reports / Issue 12/2015
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-015-0599-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content